134 related articles for article (PubMed ID: 21142294)
1. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.
Chang J; Yang W; Kahler KH; Fellers T; Orloff J; Bensimon AG; Yu AP; Fan CP; Wu EQ
Am J Cardiovasc Drugs; 2011; 11(1):21-32. PubMed ID: 21142294
[TBL] [Abstract][Full Text] [Related]
2. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
[TBL] [Abstract][Full Text] [Related]
3. Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations.
Holdiness A; Monahan K; Minor D; de Shazo RD
Am J Med; 2011 Jan; 124(1):15-9. PubMed ID: 21187182
[TBL] [Abstract][Full Text] [Related]
4. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
[TBL] [Abstract][Full Text] [Related]
5. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
Sanoski CA
Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
[TBL] [Abstract][Full Text] [Related]
7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
8. Aliskiren: an oral renin inhibitor for the treatment of hypertension.
Lam S; Choy M
Cardiol Rev; 2007; 15(6):316-23. PubMed ID: 18090068
[TBL] [Abstract][Full Text] [Related]
9. First orally active DRI Aliskiren--a new prospect in management of hypertension and beyond.
Sawhney JP
Indian Heart J; 2010; 62(1):49-56. PubMed ID: 21180035
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
11. Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry.
Kistner I; Zeymer U; Dechend R; Hagedorn I; Riemer T; Bramlage P; Pittrow D; Senges J; Schmieder RE
J Clin Hypertens (Greenwich); 2016 Oct; 18(10):1045-1053. PubMed ID: 27094460
[TBL] [Abstract][Full Text] [Related]
12. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
13. Renin inhibition with aliskiren: where are we now, and where are we going?
Azizi M; Webb R; Nussberger J; Hollenberg NK
J Hypertens; 2006 Feb; 24(2):243-56. PubMed ID: 16508564
[TBL] [Abstract][Full Text] [Related]
14. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
Horký K
Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
[TBL] [Abstract][Full Text] [Related]
15. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
16. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
18. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.
Chrysant SG
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):305-14. PubMed ID: 18327992
[TBL] [Abstract][Full Text] [Related]
19. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported.
Rosich Martí I; Allepuz A; Rodriguez Palomar G; Ortin Font F; Soler Cera M
Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):91-96. PubMed ID: 27859873
[TBL] [Abstract][Full Text] [Related]
20. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
